Intralesional cidofovir for the treatment of severe juvenile recurrent respiratory papillomatosis

Long-term results in 4 children

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

OBJECTIVE: We sought to determine the efficacy of intralesional injection of cidofovir in improving resolution of recurrent respiratory papillomatosis (RRP). STUDY DESIGN AND SETTING: We conducted a prospective, observational trial at an academic tertiary children's hospital. RESULTS: Four children with RRP requiring more than 6 surgical excisions per year were treated with intralesional cidofovir. Cidofovir (5 mg/mL) was injected into airway sites where papillomas had just been excised using sharp technique. Each patient had 6 treatments performed 6 to 8 weeks apart. Biopsies confirmed benign papilloma lesions in all cases. During treatment with intralesional cidofovir there was diminished growth of the papillomas in each patient. Once cidofovir treatment was stopped, the rate of regrowth and frequency of surgical excision returned to pretreatment levels in 3 of the 4 patients. CONCLUSIONS: Intralesional cidofovir may provide benefit in reducing the rate of RRP growth while under treatment, but RRP severity returned to pretreatment levels once cidofovir treatment was stopped using this treatment program.

Original languageEnglish (US)
Pages (from-to)788-794
Number of pages7
JournalOtolaryngology - Head and Neck Surgery
Volume128
Issue number6
DOIs
StatePublished - Jun 2003

Fingerprint

Papilloma
Therapeutics
Intralesional Injections
Growth
cidofovir
Recurrent respiratory papillomatosis
Tertiary Care Centers
Biopsy

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

@article{2d573c43bf674678a9259512a489c621,
title = "Intralesional cidofovir for the treatment of severe juvenile recurrent respiratory papillomatosis: Long-term results in 4 children",
abstract = "OBJECTIVE: We sought to determine the efficacy of intralesional injection of cidofovir in improving resolution of recurrent respiratory papillomatosis (RRP). STUDY DESIGN AND SETTING: We conducted a prospective, observational trial at an academic tertiary children's hospital. RESULTS: Four children with RRP requiring more than 6 surgical excisions per year were treated with intralesional cidofovir. Cidofovir (5 mg/mL) was injected into airway sites where papillomas had just been excised using sharp technique. Each patient had 6 treatments performed 6 to 8 weeks apart. Biopsies confirmed benign papilloma lesions in all cases. During treatment with intralesional cidofovir there was diminished growth of the papillomas in each patient. Once cidofovir treatment was stopped, the rate of regrowth and frequency of surgical excision returned to pretreatment levels in 3 of the 4 patients. CONCLUSIONS: Intralesional cidofovir may provide benefit in reducing the rate of RRP growth while under treatment, but RRP severity returned to pretreatment levels once cidofovir treatment was stopped using this treatment program.",
author = "Henry Milczuk",
year = "2003",
month = "6",
doi = "10.1016/S0194-5998(03)00259-6",
language = "English (US)",
volume = "128",
pages = "788--794",
journal = "Otolaryngology - Head and Neck Surgery (United States)",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Intralesional cidofovir for the treatment of severe juvenile recurrent respiratory papillomatosis

T2 - Long-term results in 4 children

AU - Milczuk, Henry

PY - 2003/6

Y1 - 2003/6

N2 - OBJECTIVE: We sought to determine the efficacy of intralesional injection of cidofovir in improving resolution of recurrent respiratory papillomatosis (RRP). STUDY DESIGN AND SETTING: We conducted a prospective, observational trial at an academic tertiary children's hospital. RESULTS: Four children with RRP requiring more than 6 surgical excisions per year were treated with intralesional cidofovir. Cidofovir (5 mg/mL) was injected into airway sites where papillomas had just been excised using sharp technique. Each patient had 6 treatments performed 6 to 8 weeks apart. Biopsies confirmed benign papilloma lesions in all cases. During treatment with intralesional cidofovir there was diminished growth of the papillomas in each patient. Once cidofovir treatment was stopped, the rate of regrowth and frequency of surgical excision returned to pretreatment levels in 3 of the 4 patients. CONCLUSIONS: Intralesional cidofovir may provide benefit in reducing the rate of RRP growth while under treatment, but RRP severity returned to pretreatment levels once cidofovir treatment was stopped using this treatment program.

AB - OBJECTIVE: We sought to determine the efficacy of intralesional injection of cidofovir in improving resolution of recurrent respiratory papillomatosis (RRP). STUDY DESIGN AND SETTING: We conducted a prospective, observational trial at an academic tertiary children's hospital. RESULTS: Four children with RRP requiring more than 6 surgical excisions per year were treated with intralesional cidofovir. Cidofovir (5 mg/mL) was injected into airway sites where papillomas had just been excised using sharp technique. Each patient had 6 treatments performed 6 to 8 weeks apart. Biopsies confirmed benign papilloma lesions in all cases. During treatment with intralesional cidofovir there was diminished growth of the papillomas in each patient. Once cidofovir treatment was stopped, the rate of regrowth and frequency of surgical excision returned to pretreatment levels in 3 of the 4 patients. CONCLUSIONS: Intralesional cidofovir may provide benefit in reducing the rate of RRP growth while under treatment, but RRP severity returned to pretreatment levels once cidofovir treatment was stopped using this treatment program.

UR - http://www.scopus.com/inward/record.url?scp=0038263954&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038263954&partnerID=8YFLogxK

U2 - 10.1016/S0194-5998(03)00259-6

DO - 10.1016/S0194-5998(03)00259-6

M3 - Article

VL - 128

SP - 788

EP - 794

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

SN - 0194-5998

IS - 6

ER -